recombinant zoster vaccine
AssetAlso Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), ChAdOx1-VZV, REC610, Recombinant Zoster Vaccine (CHO Cell)
Induces immunity against varicella-zoster virus using recombinant glycoprotein E with an adjuvant.
- Stage
- Phase 3
- Modality
- Vaccine
- Target
- Inflammation
- 2
- Indications
- 15
- Trials
- 5
- Developers
Indications
2Cardiovascular disease
Phase 3, Not yet recruiting, NCT07872046, clinicaltrials.gov, 15 Oct 2026
Herpes zoster
Phase 3, Active not recruiting, NCT07293065, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners5
- Trials15
- Evidence for its targets2
- Competitors12
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.